Peek J C, Graham F M, Hookham A
National Women's Hospital, Auckland.
N Z Med J. 1990 Feb 28;103(884):63-5.
Serum IgG and IgA antibodies to Chlamydia trachomatis were measured in 102 in vitro fertilisation (IVF) patients with tubal disease and in 102 infertility patients without tubal disease to assess the impact of chlamydial infection on the demand for IVF treatment in New Zealand. Sixty-five percent of the IVF patients had IgG titres greater than or equal to 1:64, compared to 24% of the controls; 29% of the IVF patients had IgA titres greater than or equal to 1:32 compared to 0% of the controls. The proportion of IVF patients with IgG antibodies increased from 39% for those from socioeconomic group 1 to 79% of those from groups 4 to 6. The difference in prevalence of IgG antibodies between the tubal and nontubal patients suggests that about 40% of the tubal infertility currently being treated by IVF has chlamydia as a causal agent. The presence of IgG or IgA antibodies did not seem to affect the chance of pregnancy in the IVF programme, nor the chance of subsequent miscarriage.
对102名患有输卵管疾病的体外受精（IVF）患者和102名无输卵管疾病的不孕症患者检测了沙眼衣原体的血清IgG和IgA抗体，以评估衣原体感染对新西兰IVF治疗需求的影响。65%的IVF患者IgG滴度大于或等于1:64，而对照组为24%；29%的IVF患者IgA滴度大于或等于1:32，而对照组为0%。IVF患者中具有IgG抗体的比例从社会经济第1组的39%增至第4至6组的79%。输卵管疾病患者和非输卵管疾病患者之间IgG抗体患病率的差异表明，目前通过IVF治疗的输卵管性不孕症中约40%由衣原体作为病因。IgG或IgA抗体的存在似乎不影响IVF程序中的妊娠几率，也不影响随后流产的几率。
